Randomized, placebo-controlled trial of AHCC for the reduction of side effects in breast cancer chemotherapy

Randomized, placebo-controlled trial of AHCC for the reduction of side effects in breast cancer chemotherapy - RCT of AHCC for the reduction of side effects in breast cancer chemotherapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008143

Enrollment

Registered

2012-06-12

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

control group placebo 10tablets/day start before 1week of FEC75 and continue 12weeks. AHCC group AHCC 10tablets/day start before 1week of FEC75 and continue 12weeks.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Diagnosed as breast cancer and treated neo-adjuvant chemotherapy "FEC75" Hemoglobin:>10.0 g/dl WBC:>3,000/mm3 and <12,000/mm3 Platelets:>100,000/mm3 AST and ALT less than 2.5 times than our standard. Serum bilirubin:>1.5 mg/dl Serum creatinin:>2.0 mg/dl

Exclusion criteria

Exclusion criteria: 1)The case who will take in functional food shown as below during FEC75 AgaricusTturmeric,Shark cartilage, Tahibo,Propolis,Shelf fungus,Coenzyme Q10,Vegetable juice,Chlorella,Fomes yucatensis,Fucoidan,Royal jelly,DHA, Aloe,PC-SPES,Saw palmetto,Bracket fungus,Selenium,Beta carotene,Isoflavone,Garlic,Black vinegar,Ginkgo biloba extract,Lactic-acid-bacteria tablet

Design outcomes

Primary

Measure	Time frame
The primary endpoint is to reduce adverse events during chemotherapy reffered CTCAE ver 4.0.	—

Countries

Japan

Contacts

Public ContactHayato Urushima

Graduate school of Medicine, Osaka University Department of Alternative & Complementary Medicine

h-urushima@cam.med.osaka-u.ac.jp06-6879-3498

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026